Literature DB >> 26350256

Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma.

Valeria Scagliotti1, Laura Avagliano2, Angelica Gualtieri3, Federica Graziola4, Patrizia Doi5, Jane Chalker6, Andrea Righini7, Marta Korbonits8, Gaetano Bulfamante9, Thomas S Jacques10,11, Valentina Massa12, Carles Gaston-Massuet13.   

Abstract

PURPOSE: Adamantinomatous craniopharyngiomas (aCPs) are complex epithelial neoplasms that arise from the progenitors of the pituitary gland. Although benign, these tumours can be locally aggressive invading vital neighbouring structures such as the hypothalamus, the cranial and optic nerves. Congenital forms of aCPs diagnosed during foetal development are very rare. The purpose of this article is to present with a histopathological and molecular characterisation of congenital craniopharyngioma.
METHODS: Here we report a case of in utero diagnosed aCP, detected at 21 weeks of gestation by ultrasound, visualised by MRI at 22 weeks and histologically diagnosed at 23 weeks. We provide with histopathological characterisation of rare form of congenital aCPs.
RESULTS: Detailed examination of the tumour reveals the classical histological hallmarks of aCPs with the presence of stellate reticulum, palisading epithelium, wet keratin and calcification deposits. The tumour demonstrated complete absence of all pituitary hormones and the absence of the neuroendocrine marker, synaptophysin. Immunohistochemistry against β-catenin revealed occasional cells with nuclear-β-catenin localisation and the presence of pituitary progenitors positive for SOX9 and SOX2. Targeted Sanger sequencing revealed no genetic variants in oncogenes CTNNB1 and BRAF, previously associated with CP.
CONCLUSIONS: In this article, we provide with in-depth molecular and histological characterisation of in utero aCP due to an unknown driving mutation that could represent a sub-cohort of congenital aCPs.

Entities:  

Keywords:  Congenital brain tumours; Craniopharyngioma; Genetics hypothalamic-pituitary axis; Pituitary gland; Pituitary tumours

Mesh:

Year:  2016        PMID: 26350256     DOI: 10.1007/s11102-015-0682-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  38 in total

1.  Fetal craniopharyngioma: early prenatal diagnosis.

Authors:  A Sosa-Olavarría; L Díaz-Guerrero; A Reigoza; A Bermúdez; M Murillo
Journal:  J Ultrasound Med       Date:  2001-07       Impact factor: 2.153

2.  Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.

Authors:  Shigeki Sekine; Tatsuhiro Shibata; Akiko Kokubu; Yukio Morishita; Masayuki Noguchi; Yukihiro Nakanishi; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts: a clinico-pathologic approach.

Authors:  Bernd M Hofmann; Jürgen Kreutzer; Wolfgang Saeger; Michael Buchfelder; Ingmar Blümcke; Rudolf Fahlbusch; Rolf Buslei
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

Review 4.  Craniopharyngiomas.

Authors:  Niki Karavitaki; Simon Cudlip; Christopher B T Adams; John A H Wass
Journal:  Endocr Rev       Date:  2006-03-16       Impact factor: 19.871

5.  beta-Catenin is expressed aberrantly in tumors expressing shadow cells. Pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst.

Authors:  Ashraf M Hassanein; Steven M Glanz; Harvey P Kessler; Thomas A Eskin; Chen Liu
Journal:  Am J Clin Pathol       Date:  2003-11       Impact factor: 2.493

Review 6.  Neonatal craniopharyngioma and inference of tumor inception time: case report and review of the literature.

Authors:  Toshinari Arai; K Ohno; Y Takada; M Aoyagi; K Hirakawa
Journal:  Surg Neurol       Date:  2003-09

7.  Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans.

Authors:  Carles Gaston-Massuet; Cynthia Lilian Andoniadou; Massimo Signore; Sujatha A Jayakody; Nicoletta Charolidi; Roger Kyeyune; Bertrand Vernay; Thomas S Jacques; Makoto Mark Taketo; Paul Le Tissier; Mehul T Dattani; Juan Pedro Martinez-Barbera
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-02       Impact factor: 11.205

8.  Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential.

Authors:  Cynthia Lilian Andoniadou; Danielle Matsushima; Seyedeh Neda Mousavy Gharavy; Massimo Signore; Albert Ian Mackintosh; Marie Schaeffer; Carles Gaston-Massuet; Patrice Mollard; Thomas Stanley Jacques; Paul Le Tissier; Mehul Tulsidas Dattani; Larysa Halyna Pevny; Juan Pedro Martinez-Barbera
Journal:  Cell Stem Cell       Date:  2013-10-03       Impact factor: 24.633

9.  Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.

Authors:  Cynthia L Andoniadou; Carles Gaston-Massuet; Rukmini Reddy; Ralph P Schneider; Maria A Blasco; Paul Le Tissier; Thomas S Jacques; Larysa H Pevny; Mehul T Dattani; Juan Pedro Martinez-Barbera
Journal:  Acta Neuropathol       Date:  2012-02-18       Impact factor: 17.088

10.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.

Authors:  Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

View more
  8 in total

Review 1.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

2.  The epidemiology and management patterns of pediatric pituitary tumors in the United States.

Authors:  Luz E Castellanos; Madhusmita Misra; Timothy R Smith; Edward R Laws; J Bryan Iorgulescu
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 4.107

Review 3.  Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis.

Authors:  Jose Mario Gonzalez-Meljem; Juan Pedro Martinez-Barbera
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

4.  Pathological and Topographical Classification of Craniopharyngiomas: A Literature Review.

Authors:  James Lubuulwa; Ting Lei
Journal:  J Neurol Surg Rep       Date:  2016-07

Review 5.  Recent advances in molecular pathology of craniopharyngioma.

Authors:  Sarah Larkin; Niki Karavitaki
Journal:  F1000Res       Date:  2017-07-24

6.  Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.

Authors:  Vivian Thimsen; Nora John; Michael Buchfelder; Jörg Flitsch; Rudolf Fahlbusch; Harald Stefanits; Engelbert Knosp; Marco Losa; Rolf Buslei; Annett Hölsken
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

7.  From fix to fit into the autoptic human brains.

Authors:  Beatrice Paradiso; Michele Simonato; Gaetano Thiene; Anna Lavezzi
Journal:  Eur J Histochem       Date:  2018-08-27       Impact factor: 3.188

8.  Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.

Authors:  Pinaki Dutta; Carles Gaston-Massuet; Ashutosh Rai; Soujanya D Yelamanchi; Bishan D Radotra; Sunil K Gupta; Kanchan K Mukherjee; Manjul Tripathi; Rajesh Chhabra; Chirag K Ahuja; Narendra Kumar; Akhilesh Pandey; Márta Korbonits
Journal:  Acta Neuropathol Commun       Date:  2022-09-16       Impact factor: 7.578

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.